Results for “fda-drug-labels”

Queries the ClinPGx REST API for pharmacogenomic gene-drug data, clinical annotations, CPIC guidelines, and FDA drug labels, generating markdown reports with CSV tables.

Query the openFDA API for drugs, medical devices, adverse event reports, recalls, regulatory submissions (510k, PMA), and substance identification (UNII). Use when searching FDA safety data, pharmacovigilance and adverse-event signals, device clearances, drug labels, or recall records for regulatory data analysis and safety research. Part of the AlterLab Academic Skills suite.

We need to output a SKILL.md file with the specified format.

Access ClinPGx pharmacogenomics data (the successor to PharmGKB) to query gene-drug interactions, CPIC/DPWG dosing guidelines, drug labels, and pharmacogene records. Use when interpreting pharmacogenes (CYP2D6, CYP2C19, TPMT, DPYD, SLCO1B1), looking up genotype-guided drug dosing, checking PGx drug-safety associations (e.g. HLA-B*57:01 and abacavir), or supporting precision medicine and clinical pharmacogenomics decisions. For star-allele definitions/frequencies see PharmVar; for germline/somatic variant pathogenicity see alterlab-clinvar. Part of the AlterLab Academic Skills suite.

Search NHTSA vehicle recalls, FDA food/drug recalls, and CFPB consumer complaints via an MCP server for product safety monitoring.

Drafts U.S. HACCP plans for food production under FDA or USDA regimes. Triggers on requests involving HACCP plans, food safety plans, hazard analysis, critical control points, FSMA compliance, seafood HACCP (21 CFR 123), or meat/poultry HACCP (9 CFR 417).

Therapeutics Data Commons. Conjuntos de dados prontos para IA em descoberta de drogas (ADME, toxicidade, DTI), benchmarks, divisões de scaffold, oráculos moleculares, para ML terapêutico e predição farmacológica.

Query the Open Targets Platform GraphQL API for target-disease associations, tractability and safety data, genetics/omics evidence, and known drugs. Use when identifying or prioritizing therapeutic drug targets, assessing target druggability/safety, or gathering target-disease evidence for drug discovery. Part of the AlterLab Academic Skills suite.

Maps the US federal privacy landscape including sectoral laws (HIPAA, GLBA, FERPA, COPPA, FCRA, ECPA, VPPA), FTC Section 5 enforcement, proposed federal comprehensive legislation, and the interaction between federal and state privacy regimes. Keywords: federal privacy, HIPAA, GLBA, FERPA, COPPA, FCRA, FTC, sectoral, preemption.

Identifies a medication from a photo and generates a genotype-informed dosage card using CPIC guidelines and real 23andMe data.

Access and analyze drug information from the DrugBank database — drug properties, interactions, targets, pathways, chemical structures, and pharmacology data. Use when working with pharmaceutical data, drug discovery research, drug-drug interaction analysis, target identification, chemical similarity searches, ADMET predictions, or any task needing detailed drug and drug-target records from DrugBank. Part of the AlterLab Academic Skills suite.

Draft an internal legal research memo for the supervising attorney with verified authority and flagged open questions.

Use when you need to annotate BAM alignments with a two-character tag based on overlaps with BED, GFF, or VCF annotation files, such as labeling reads by feature class or interval source.

Applies medicinal-chemistry filters with the medchem library — drug-likeness rules (Lipinski, Veber), PAINS filters, structural alerts, and molecular complexity metrics for compound prioritization and library cleanup. Use when filtering or triaging a compound library, flagging PAINS or reactive groups, or assessing drug-likeness of candidate molecules. Part of the AlterLab Academic Skills suite.

Prepares for FDA QSR audits by asking six forcing questions covering complaints, process validation, DHRs, CAPAs, labeling, and Form 483 history.

Access the ZINC database of 230M+ commercially available (purchasable) compounds, searching by ZINC ID or SMILES, running similarity searches, and downloading 3D-ready structures. Use when assembling a compound library for virtual screening, finding purchasable analogs, or obtaining docking-ready 3D structures for drug discovery. Part of the AlterLab Academic Skills suite.

Recommends weight‑losing and weight‑neutral medications as first‑ and second‑line agents for managing overweight/obese patients with type 2 diabetes. Triggers include when a clinician asks, 'Which diabetes medications will not worsen weight in this obese patient?' or 'Should I avoid sulfonylureas in this patient with T2DM and obesity due to weight gain risk?'

Guides dose escalation for obesity pharmacotherapy based on efficacy and tolerability while staying within approved upper dose limits. Triggers include clinician questions like "How should I titrate naltrexone/bupropion if the starting dose is tolerated?" or "What is the maximum liraglutide dose I can use?"

Set up and manage data labeling workflows using manual annotation tools, semi-automated pipelines, active learning, and programmatic weak supervision. Use when the user requests data labeling or provides relevant inputs for this workflow.

Form Labels and Helper Text

Provides verified official legal references for business formation, labor, and privacy across the USA, Canada, and all 27 EU member states, with links to government portals and gazettes.

Drafts FDA product recall plans compliant with 21 CFR Part 7, covering Recall Committee governance, health hazard evaluation, recall classification, notification protocols, effectiveness checks, product disposition, and termination procedures. Use when developing recall SOPs, updating recall procedures, drafting recall readiness plans, or preparing FDA-regulated product recall documentation.

Audit and fix HTML metadata including page titles, meta descriptions, canonical URLs, Open Graph tags, Twitter cards, favicons, JSON-LD structured data, and robots directives.

Loads Therapeutics Data Commons (TDC, PyTDC) AI-ready drug-discovery datasets and benchmarks — ADME, toxicity, drug-target interaction (DTI), scaffold splits, and molecular oracles for therapeutic ML and pharmacological prediction. Use when fetching a standardized benchmark dataset, applying scaffold or cold-split evaluation, or sourcing labeled molecules for ADMET, toxicity, or DTI modeling. Sources data, splits, and oracles only — defer molecular featurization (ECFP/fingerprints), model training, and transformers to a molecular-ML skill (e.g. deepchem). Part of the AlterLab Academic Skills suite.

Use this skill when the user asks about the FMCSA Drug & Alcohol Clearinghouse — full vs limited query, pre-employment vs annual query, query credit purchasing, who has access (employers, drivers, MROs, SAPs, state licensing agencies), reporting violations to the Clearinghouse, the "prohibited" status workflow, consent forms, or how to register/use the clearinghouse.fmcsa.dot.gov portal. Cite 49 CFR 382.701-727.

Therapeutics Data Commons. AI-ready drug discovery datasets (ADME, toxicity, DTI), benchmarks, scaffold splits, molecular oracles, for therapeutic ML and pharmacological prediction.

Filters and prioritizes compound libraries in drug discovery using drug-likeness rules, structural alerts, complexity metrics, and a query language.

Search the Federal Register for rules, proposed rules, notices, and presidential documents, and monitor regulatory activity.

Therapeutics Data Commons. AI-ready drug discovery datasets (ADME, toxicity, DTI), benchmarks, scaffold splits, molecular oracles, for therapeutic ML and pharmacological prediction.

Apply medicinal chemistry filters for compound triage: drug-likeness rules (Lipinski, Veber, CNS), structural alert catalogs (PAINS, NIBR, ChEMBL), complexity metrics, and a custom query language for library filtering.

Therapeutics Data Commons. AI-ready drug discovery datasets (ADME, toxicity, DTI), benchmarks, scaffold splits, molecular oracles, for therapeutic ML and pharmacological prediction.

Implements 42 CFR Part 2 protections for substance use disorder patient records. Covers written consent requirements stricter than HIPAA, re-disclosure prohibition, court order procedures, qualified service organization agreements, and 2024 amendments aligning Part 2 with HIPAA. Keywords: 42 CFR Part 2, substance use disorder, SUD records, re-disclosure, consent, Part 2 amendments.

Access AI-ready drug discovery datasets and benchmarks from Therapeutics Data Commons, covering ADME, toxicity, drug-target interactions, and molecular generation with standardized splits and evaluation metrics.

Generate professional clinical decision support documents for pharmaceutical and clinical research, including biomarker-stratified cohort analyses and evidence-based treatment recommendation reports with GRADE grading, statistical analysis, and publication-ready LaTeX/PDF output.

Recommends ACE inhibitors, ARBs, or calcium channel blockers as first-line hypertension therapy rather than β‑adrenergic blockers in obese patients with type 2 diabetes. Triggers include when a clinician asks, 'What antihypertensive should I start for this obese patient with T2DM to avoid weight gain?' or 'Should I avoid β‑blockers in this patient with diabetes and hypertension?'